Hyoung Chul Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hyoung Chul Choi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Jin Young Sung
Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 42415, Korea
17 shared publicationsSeul Gi Kim
Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 42415, Korea
14 shared publicationsJae-Ryong Kim
Senotherapy-based Metabolic Disease Control Research Center, College of Medicine, Yeungnam University, Daegu, Republic of Korea
11 shared publicationsYoung Jin Kang
Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea
6 shared publicationsKwang Youn Lee
Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 705-717, Korea
5 shared publicationsKyung Young Lee
Department of Pharmacology, College of Medicine, Yeungnam University, 170 Hyunchung-Ro, Nam-Gu, Daegu 42415, Republic of Korea; Smart-aging Convergence Research Center, College of Medicine, Yeungnam University, 170 Hyunchung-Ro, Nam-Gu, Daegu 42415, Republic of Korea
5 shared publications
Latest Publications
- Open Access
- 24 July 2025
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 29 (5) , 659-667
Procyanidin B2-induced LKB1-AMPK activation mitigates vascular smooth muscle cell proliferation through inhibition of mTOR signaling
Vascular smooth muscle cell (VSMC) proliferation contributes to intimal thickening in atherosclerosis and restenosis diseases. As a proanthocyanidin type B, procyanidin B2 (PB2) is abundantly found in cocoa, apples, and grapes and is reported to have vascular protective effects. However, the mechanisms by which PB2 inhibits proliferation of VSMCs are not clearly understood. Therefore, the purpose of this study was to investigate the underlying mechanism of PB2-induced inhibition of cell proliferation in VSMCs. We found that PB2 dose- and time-dependently increased phosphorylation of liver kinase B1 (LKB1) and AMP-activated protein kinase (AMPK) in VSMCs. AMPK is a serine-threonine kinase and serves as a key sensor of cellular energy. PB2 induced LKB1 translocation from nucleus to cytosol which led to AMPK activation. In addition, PB2-induced AMPK activation decreased cell proliferation and cell cycle progression by inhibiting mammalian target of rapamycin signaling pathway. Transfection with LKB1 or AMPK siRNA and transduction of dominant-negative isoforms of the α1 and α2 subunits of AMPK eliminated anti-proliferative effects of PB2. These results demonstrate that PB2 might be a preventive agent for cardiovascular disorders such as atherosclerosis and hypertension.
- 24 July 2025
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 29 (5) , 659-667
Open AccessProcyanidin B2-induced LKB1-AMPK activation mitigates vascular smooth muscle cell proliferation through inhibition of mTOR signaling
Vascular smooth muscle cell (VSMC) proliferation contributes to intimal thickening in atherosclerosis and restenosis diseases. As a proanthocyanidin type B, procyanidin B2 (PB2) is abundantly found in cocoa, apples, and grapes and is reported to have vascular protective effects. However, the mechanisms by which PB2 inhibits proliferation of VSMCs are not clearly understood. Therefore, the purpose of this study was to investigate the underlying mechanism of PB2-induced inhibition of cell proliferation in VSMCs. We found that PB2 dose- and time-dependently increased phosphorylation of liver kinase B1 (LKB1) and AMP-activated protein kinase (AMPK) in VSMCs. AMPK is a serine-threonine kinase and serves as a key sensor of cellular energy. PB2 induced LKB1 translocation from nucleus to cytosol which led to AMPK activation. In addition, PB2-induced AMPK activation decreased cell proliferation and cell cycle progression by inhibiting mammalian target of rapamycin signaling pathway. Transfection with LKB1 or AMPK siRNA and transduction of dominant-negative isoforms of the α1 and α2 subunits of AMPK eliminated anti-proliferative effects of PB2. These results demonstrate that PB2 might be a preventive agent for cardiovascular disorders such as atherosclerosis and hypertension.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Differential expression of PPARγ by pioglitazone and telmisartan causes effect of disparity on mTORC2-mediated cell proliferation and migration
Excessive cell proliferation and migration of vascular smooth muscle cells (VSMCs) exacerbate atherosclerotic plaque formation. Peroxisome proliferation-activated receptor gamma (PPARγ) has an atheroprotective effect by inhibiting foam cell formation in macrophages. However, the anti-proliferative mechanism of PPARγ has not been fully explained in VSMCs. Therefore, we investigated the effect of PPARγ by full or partial agonist on VSMC proliferation and migration to suppress atherosclerosis. We found that PPARγ activation by pioglitazone (a full agonist) decreased PDGF-BB-induced mTORC2 signaling pathway and cell proliferation. Pioglitazone treatment downregulated the expression of VSMC contractile markers, cell migration, and lipid accumulation. In contrast, a PPARγ partial agonist, telmisartan, did not influence mTORC2 signaling pathway, VSMC phenotype switching, and lipid droplet markers despite PPARγ activation. We identified differential expression of PPARγ between pioglitazone and telmisartan to regulate VSMC phenotype switching and atherosclerosis. The anti-proliferative effect of pioglitazone was attributed to inhibition of mTORC2 activation, leading to atheroprotective effect. Our findings show that PPARγ suppresses mTORC2 signaling pathway to mitigate VSMC proliferation and migration, which accelerates the atherosclerosis development. These results demonstrate that full and partial PPARγ agonists exert different effects through specific mechanisms, respectively, despite both agonists against PPARγ.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessDifferential expression of PPARγ by pioglitazone and telmisartan causes effect of disparity on mTORC2-mediated cell proliferation and migration
Excessive cell proliferation and migration of vascular smooth muscle cells (VSMCs) exacerbate atherosclerotic plaque formation. Peroxisome proliferation-activated receptor gamma (PPARγ) has an atheroprotective effect by inhibiting foam cell formation in macrophages. However, the anti-proliferative mechanism of PPARγ has not been fully explained in VSMCs. Therefore, we investigated the effect of PPARγ by full or partial agonist on VSMC proliferation and migration to suppress atherosclerosis. We found that PPARγ activation by pioglitazone (a full agonist) decreased PDGF-BB-induced mTORC2 signaling pathway and cell proliferation. Pioglitazone treatment downregulated the expression of VSMC contractile markers, cell migration, and lipid accumulation. In contrast, a PPARγ partial agonist, telmisartan, did not influence mTORC2 signaling pathway, VSMC phenotype switching, and lipid droplet markers despite PPARγ activation. We identified differential expression of PPARγ between pioglitazone and telmisartan to regulate VSMC phenotype switching and atherosclerosis. The anti-proliferative effect of pioglitazone was attributed to inhibition of mTORC2 activation, leading to atheroprotective effect. Our findings show that PPARγ suppresses mTORC2 signaling pathway to mitigate VSMC proliferation and migration, which accelerates the atherosclerosis development. These results demonstrate that full and partial PPARγ agonists exert different effects through specific mechanisms, respectively, despite both agonists against PPARγ.
- Open Access
- 2 September 2024
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (9) , 1967-1979
Telomere stabilization by metformin mitigates the progression of atherosclerosis via the AMPK-dependent p-PGC-1α pathway
Telomere dysfunction is a well-known molecular trigger of senescence and has been associated with various age-related diseases, including atherosclerosis. However, the mechanisms involved have not yet been elucidated, and the extent to which telomeres contribute to atherosclerosis is unknown. Therefore, we investigated the mechanism of metformin-induced telomere stabilization and the ability of metformin to inhibit vascular smooth muscle cell (VSMC) senescence caused by advanced atherosclerosis. The present study revealed that metformin inhibited the phenotypes of atherosclerosis and senescence in VSMCs. Metformin increased the phosphorylation of AMPK-dependent PGC-1α and thus increased telomerase activity and the protein level of TERT in OA-treated VSMCs. Mechanistically, the phosphorylation of AMPK and PGC-1α by metformin not only enhanced telomere function but also increased the protein level of TERT, whereas TERT knockdown accelerated the development of atherosclerosis and senescent phenotypes in OA-treated VSMCs regardless of metformin treatment. Furthermore, the in vivo results showed that metformin attenuated the formation of atherosclerotic plaque markers in the aortas of HFD-fed ApoE KO mice. Although metformin did not reduce plaque size, it inhibited the phosphorylation of the AMPK/PGC-1α/TERT signaling cascade, which is associated with the maintenance and progression of plaque formation, in HFD-fed ApoE KO mice. Accordingly, metformin inhibited atherosclerosis-associated phenotypes in vitro and in vivo. These observations show that the enhancement of telomere function by metformin is involved in specific signaling pathways during the progression of atherosclerosis. These findings suggest that telomere stabilization by metformin via the AMPK/p-PGC-1α pathway might provide a strategy for developing therapeutics against vascular diseases such as atherosclerosis.
- 2 September 2024
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (9) , 1967-1979
Open AccessTelomere stabilization by metformin mitigates the progression of atherosclerosis via the AMPK-dependent p-PGC-1α pathway
Telomere dysfunction is a well-known molecular trigger of senescence and has been associated with various age-related diseases, including atherosclerosis. However, the mechanisms involved have not yet been elucidated, and the extent to which telomeres contribute to atherosclerosis is unknown. Therefore, we investigated the mechanism of metformin-induced telomere stabilization and the ability of metformin to inhibit vascular smooth muscle cell (VSMC) senescence caused by advanced atherosclerosis. The present study revealed that metformin inhibited the phenotypes of atherosclerosis and senescence in VSMCs. Metformin increased the phosphorylation of AMPK-dependent PGC-1α and thus increased telomerase activity and the protein level of TERT in OA-treated VSMCs. Mechanistically, the phosphorylation of AMPK and PGC-1α by metformin not only enhanced telomere function but also increased the protein level of TERT, whereas TERT knockdown accelerated the development of atherosclerosis and senescent phenotypes in OA-treated VSMCs regardless of metformin treatment. Furthermore, the in vivo results showed that metformin attenuated the formation of atherosclerotic plaque markers in the aortas of HFD-fed ApoE KO mice. Although metformin did not reduce plaque size, it inhibited the phosphorylation of the AMPK/PGC-1α/TERT signaling cascade, which is associated with the maintenance and progression of plaque formation, in HFD-fed ApoE KO mice. Accordingly, metformin inhibited atherosclerosis-associated phenotypes in vitro and in vivo. These observations show that the enhancement of telomere function by metformin is involved in specific signaling pathways during the progression of atherosclerosis. These findings suggest that telomere stabilization by metformin via the AMPK/p-PGC-1α pathway might provide a strategy for developing therapeutics against vascular diseases such as atherosclerosis.
- 18 January 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1869 (3) , 159453
SIRT1-dependent PGC-1α deacetylation by SRT1720 rescues progression of atherosclerosis by enhancing mitochondrial function
- 18 January 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1869 (3) , 159453
SIRT1-dependent PGC-1α deacetylation by SRT1720 rescues progression of atherosclerosis by enhancing mitochondrial function
- 27 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115892
PPARγ activation by fisetin mitigates vascular smooth muscle cell senescence via the mTORC2-FoxO3a-autophagy signaling pathway
- 27 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115892
PPARγ activation by fisetin mitigates vascular smooth muscle cell senescence via the mTORC2-FoxO3a-autophagy signaling pathway
- 11 January 2023
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 108, 104927
Fisetin alleviates cellular senescence through PTEN mediated inhibition of PKCδ-NOX1 pathway in vascular smooth muscle cells
- 11 January 2023
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 108, 104927
Fisetin alleviates cellular senescence through PTEN mediated inhibition of PKCδ-NOX1 pathway in vascular smooth muscle cells
- 1 December 2021
- Published by Elsevier in Experimental Gerontology
- Vol. 156, 111598
Fisetin-induced PTEN expression reverses cellular senescence by inhibiting the mTORC2-Akt Ser473 phosphorylation pathway in vascular smooth muscle cells
- 1 December 2021
- Published by Elsevier in Experimental Gerontology
- Vol. 156, 111598
Fisetin-induced PTEN expression reverses cellular senescence by inhibiting the mTORC2-Akt Ser473 phosphorylation pathway in vascular smooth muscle cells
- Open Access
- 30 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0239976
Prednisolone suppresses adriamycin-induced vascular smooth muscle cell senescence and inflammatory response via the SIRT1-AMPK signaling pathway
Cellular senescence is associated with inflammation and the senescence-associated secretory phenotype (SASP) of secreted proteins. Vascular smooth muscle cell (VSMC) expressing the SASP contributes to chronic vascular inflammation, loss of vascular function, and the developments of age-related diseases. Although VSMC senescence is well recognized, the mechanism of VSMC senescence and inflammation has not been established. In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway. We found that PD inhibited ADR-induced VSMC senescence and inflammation response by decreasing p-NF-κB expression through the SIRT1-AMPK signaling pathway. In addition, Western blotting revealed PD not only increased SIRT1 expression but also increased the phosphorylation of AMPK at Ser485 in ADR-treated VSMC. Furthermore, siRNA-mediated downregulation or pharmacological inhibitions of SIRT1 or AMPK significantly augmented ADR-induced inflammatory response and senescence in VSMC despite PD treatment. In contrast, the overexpression of SIRT1 or constitutively active AMPKα (CA-AMPKα) attenuated cellular senescence and p-NF-κB expression. Taken together, the inhibition of p-NF-κB by PD through the SIRT1 and p-AMPK (Ser485) pathway suppressed VSMC senescence and inflammation. Collectively, our results suggest that anti-aging effects of PD are caused by reduced VSMC senescence and inflammation due to reciprocal regulation of the SIRT1/p-AMPK (Ser485) signaling pathway.
- 30 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0239976
Open AccessPrednisolone suppresses adriamycin-induced vascular smooth muscle cell senescence and inflammatory response via the SIRT1-AMPK signaling pathway
Cellular senescence is associated with inflammation and the senescence-associated secretory phenotype (SASP) of secreted proteins. Vascular smooth muscle cell (VSMC) expressing the SASP contributes to chronic vascular inflammation, loss of vascular function, and the developments of age-related diseases. Although VSMC senescence is well recognized, the mechanism of VSMC senescence and inflammation has not been established. In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway. We found that PD inhibited ADR-induced VSMC senescence and inflammation response by decreasing p-NF-κB expression through the SIRT1-AMPK signaling pathway. In addition, Western blotting revealed PD not only increased SIRT1 expression but also increased the phosphorylation of AMPK at Ser485 in ADR-treated VSMC. Furthermore, siRNA-mediated downregulation or pharmacological inhibitions of SIRT1 or AMPK significantly augmented ADR-induced inflammatory response and senescence in VSMC despite PD treatment. In contrast, the overexpression of SIRT1 or constitutively active AMPKα (CA-AMPKα) attenuated cellular senescence and p-NF-κB expression. Taken together, the inhibition of p-NF-κB by PD through the SIRT1 and p-AMPK (Ser485) pathway suppressed VSMC senescence and inflammation. Collectively, our results suggest that anti-aging effects of PD are caused by reduced VSMC senescence and inflammation due to reciprocal regulation of the SIRT1/p-AMPK (Ser485) signaling pathway.